NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) Given Consensus Recommendation of “Moderate Buy” by Analysts

Shares of NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) have been given an average rating of “Moderate Buy” by the five research firms that are currently covering the company, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, two have given a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year price objective among brokers that have issued ratings on the stock in the last year is $8.50.

Separately, Weiss Ratings lowered shares of NeuroSense Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, July 30th.

Insider Buying and Selling at NeuroSense Therapeutics

In related news, CFO Or Eisenberg purchased 250,000 shares of NeuroSense Therapeutics stock in a transaction dated Tuesday, June 16th. The shares were acquired at an average price of $0.80 per share, with a total value of $200,000.00. Following the completion of the transaction, the chief financial officer owned 1,504,050 shares of the company’s stock, valued at approximately $1,203,240. This trade represents a 19.94% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Alon Ben-Noon purchased 250,000 shares of NeuroSense Therapeutics stock in a transaction dated Tuesday, June 16th. The shares were bought at an average cost of $0.80 per share, for a total transaction of $200,000.00. Following the transaction, the chief executive officer directly owned 4,534,233 shares of the company’s stock, valued at approximately $3,627,386.40. The trade was a 5.84% increase in their position. The disclosure for this purchase is available in the SEC filing. 27.40% of the stock is owned by company insiders.

Institutional Trading of NeuroSense Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the company. Two Sigma Investments LP bought a new position in NeuroSense Therapeutics during the 3rd quarter worth approximately $26,000. Jane Street Group LLC acquired a new position in shares of NeuroSense Therapeutics in the 2nd quarter worth approximately $54,000. Yorkville Advisors Global LP bought a new stake in shares of NeuroSense Therapeutics in the 4th quarter valued at approximately $77,000. Finally, Squarepoint Ops LLC increased its holdings in shares of NeuroSense Therapeutics by 91.0% in the 3rd quarter. Squarepoint Ops LLC now owns 95,375 shares of the company’s stock valued at $119,000 after acquiring an additional 45,450 shares during the last quarter. Institutional investors and hedge funds own 1.04% of the company’s stock.

NeuroSense Therapeutics Trading Down 7.2%

NeuroSense Therapeutics stock opened at $0.50 on Friday. The stock has a market cap of $19.00 million, a P/E ratio of -0.93 and a beta of 1.62. The stock has a 50 day moving average of $0.69 and a 200-day moving average of $0.79. NeuroSense Therapeutics has a 52 week low of $0.39 and a 52 week high of $1.98.

NeuroSense Therapeutics Company Profile

NeuroSense Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies for neurodegenerative and age-related neurological disorders. The company’s primary mission is to address unmet medical needs in diseases characterized by protein aggregation, chronic inflammation and cellular senescence in the central nervous system.

At the core of NeuroSense’s approach is a proprietary senotherapeutic platform designed to selectively target and clear senescent cells that contribute to neurodegeneration.